Novo Nordisk Partners With AWS to Accelerate AI‑Driven Drug Discovery

Novo Nordisk announces partnership with Amazon Web Services at a joint press event, committing to cloud‑based AI tools for early‑stage drug design and promising to shorten discovery cycles while sharing research teams across both companies.

AWS will supply scalable compute power and pre‑built machine‑learning models that predict molecular properties, enabling researchers to run billions of simulations daily and screen millions of compounds far faster than traditional lab methods.

The collaboration targets diseases with high unmet need, such as obesity and rare genetic disorders, and plans to embed AI insights into Novo Nordisk’s pipeline to accelerate candidate selection and move promising drugs into clinical testing sooner.

Industry analysts say merging pharma expertise with cloud AI could cut early‑research costs by double‑digit percentages, speed time‑to‑market, and set a benchmark for other drug makers pursuing digital transformation in the competitive biotech sector.